Compare MAIA & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIA | PETS |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 36.8M |
| IPO Year | 2022 | N/A |
| Metric | MAIA | PETS |
|---|---|---|
| Price | $1.21 | $1.75 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | ★ 446.4K | 216.6K |
| Earning Date | 11-07-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $226,972,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.59 |
| 52 Week High | $2.74 | $6.85 |
| Indicator | MAIA | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 35.24 |
| Support Level | $1.07 | $1.69 |
| Resistance Level | $1.46 | $1.83 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 62.71 | 29.79 |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.